In summary, our data demonstrate that plerixafor is an effective inhibitor of CXCR4 in pediatric ALL and that the timing of administration may be critical to optimizing its use as a chemosensitizing agent in leukemia. The gene discussed is CXCR4; the disease is leukemia.